PsoriasisNCT07816575
Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque Psoriasis
A study testing Alpha Hydroxy Acids with nanocarriers, Alpha Hydroxy Acids only. and Calcipotriol plus betamethasone in people with Psoriasis, run by Al-Azhar University at 1 site in Egypt.
Trial summary
The aim of this double blind comparative clinical study is to evaluate the efficacy of AHAs combined with nanocarriers and their use as a non steroidal alternative drug for long term management of plaque psoriasis Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Psoriasis
- What is being tested?
- Alpha Hydroxy Acids with nanocarriers, Alpha Hydroxy Acids only. and Calcipotriol plus betamethasone
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Mar 2024to 10 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Severe irritation and highly inflamed skin.
- Pregnant and lactating females.
- Patients with acute renal insufficiency.
- Face, flexural and groin lesions.
Trial locations and contacts
1 site in 1 country.
About this study
The aim of this double blind comparative clinical study is to evaluate the efficacy of AHAs combined with nanocarriers and their use as a non steroidal alternative drug for long term management of plaque psoriasis
- Conditions
- Psoriasis
- Being tested
- Alpha Hydroxy Acids with nanocarriers, Alpha Hydroxy Acids only., Calcipotriol plus betamethasone, Placebo.
- Medical subject headings
- Psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Alpha Hydroxy Acids with nanocarriersDrug
Topical Alpha Hydroxy Acids formulated with nanocarriers applied to psoriatic plaques.
Alpha Hydroxy Acids only.Drug
Topical Alpha Hydroxy Acids only applied to psoriatic plaques.
Calcipotriol plus betamethasoneDrug
Topical calcipotriol plus betamethasone ointment applied to psoriatic plaques.
Placebo.Other
Vehicle control / Placebo topical application applied to psoriatic plaques
| Study group | Role | What they receive |
|---|---|---|
| Alpha Hydroxy Acids with Nanocarriers Group | Experimental | Patients received Alpha Hydroxy Acids formulated with nanocarriers. Receives: Drug: Alpha Hydroxy Acids with nanocarriers |
| Alpha Hydroxy Acids Group. | Experimental | Patients received Alpha Hydroxy Acids only. Receives: Drug: Alpha Hydroxy Acids only. |
| Calcipotriol plus betamethasone Group. | Active comparator | Patients received calcipotriol plus betamethasone. Receives: Drug: Calcipotriol plus betamethasone |
| Placebo Group | Placebo comparator | Patients received placebo comparator. Receives: Other: Placebo. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage Change in PASI Score.
Reduction in PASI score from baseline to week 8.
Measured: Baseline and 8 weeks
Secondary outcomes (1)
Dermatology Life Quality Index (DLQI)
Changes in DLQI score to assess the impact of treatment on patients' quality of life.
Measured: Baseline and 8 weeks).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2026
- Study start15 Mar 2024
- Primary completion3 Jul 2025
- Study completion10 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PsoriasisStudies of the same condition, open and under way.
- More trials run by Al-Azhar UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Al-Azhar University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bodour Kamal Elshenawy, Al-Azhar University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07816575
- Sponsor's protocol ID
- AHAs,Nanocarriers in psoriasis
- Status last verified
- Sep 2026
- First submitted
- 8 Sep 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque Psoriasis
- ClinicalTrials.gov ID
- NCT07816575
- Acronym / sponsor ID
- AHAs,Nanocarriers in psoriasis
- Conditions
- Psoriasis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Al-Azhar UniversityUniversity, hospital or other
- Study start
- 15 Mar 2024 (actual)
- Primary completion
- 3 Jul 2025 (actual)
- Study completion
- 10 Sep 2025 (actual)
- First posted
- 11 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this double blind comparative clinical study is to evaluate the efficacy of AHAs combined with nanocarriers and their use as a non steroidal alternative drug for long term management of plaque psoriasis
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Alpha Hydroxy Acids with Nanocarriers Group | Experimental | Drug: Alpha Hydroxy Acids with nanocarriersPatients received Alpha Hydroxy Acids formulated with nanocarriers. |
| Alpha Hydroxy Acids Group. | Experimental | Drug: Alpha Hydroxy Acids only.Patients received Alpha Hydroxy Acids only. |
| Calcipotriol plus betamethasone Group. | Active comparator | Drug: Calcipotriol plus betamethasonePatients received calcipotriol plus betamethasone. |
| Placebo Group | Placebo comparator | Other: Placebo.Patients received placebo comparator. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (4 listed)
- Severe irritation and highly inflamed skin.
- Pregnant and lactating females.
- Patients with acute renal insufficiency.
- Face, flexural and groin lesions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Alpha Hydroxy Acids with nanocarriersTopical Alpha Hydroxy Acids formulated with nanocarriers applied to psoriatic plaques. | Drug | Alpha Hydroxy Acids with Nanocarriers Group |
| Alpha Hydroxy Acids only.Topical Alpha Hydroxy Acids only applied to psoriatic plaques. | Drug | Alpha Hydroxy Acids Group. |
| Calcipotriol plus betamethasoneTopical calcipotriol plus betamethasone ointment applied to psoriatic plaques. | Drug | Calcipotriol plus betamethasone Group. |
| Placebo.Vehicle control / Placebo topical application applied to psoriatic plaques | Other | Placebo Group |
Primary outcome
Percentage Change in PASI Score.
Time frame: Baseline and 8 weeks
Reduction in PASI score from baseline to week 8.
1 secondary outcome
Dermatology Life Quality Index (DLQI)
Time frame: Baseline and 8 weeks).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Psoriasis
Active, not recruitingObservational study
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Psoriasis
Not yet recruitingPhase 1
Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation
Psoriasis, Arthritis, Psoriatic
Active, not recruitingPhase 1
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
RecruitingPhase 1
A Study of HL40626S Tablets in Healthy Adults
Skin Disease, Immune System Disease
RecruitingObservational study
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
Primary Immunodeficiency, Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Alpha Hydroxy Acids with nanocarriers, Alpha Hydroxy Acids only. and Calcipotriol plus betamethasone in people with Psoriasis, run by Al-Azhar University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage Change in PASI Score. (time frame: Baseline and 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.